newsfilter
← Latest News
GlobeNewswire·

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2